Bio-orthogonal chemical reactions for environmental applications

Publication ID: 24-11857636_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Bio-orthogonal chemical reactions for environmental applications,” Published Technical Disclosure No. 24-11857636_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857636_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,636.

Summary of the Inventive Concept

The inventive concept applies the bio-orthogonal drug activation technology to environmental applications, enabling targeted and controlled release of pesticides, pollutant-degrading enzymes, bioremediation agents, and wastewater treatment agents.

Background and Problem Solved

The original patent disclosed the use of bio-orthogonal chemical reactions for therapeutic applications, but this technology has limitations in terms of its applicability to environmental problems. The new inventive concept addresses this limitation by adapting the core technology to tackle environmental issues, such as pest control, pollution, and wastewater treatment.

Detailed Description of the Inventive Concept

The inventive concept involves the use of prodrugs comprising a bio-orthogonal chemical reaction trigger, such as a trans-cyclooctene derivative, and a diene activator, such as a tetrazine derivative. Upon cyclooaddition of the trigger and activator, the prodrug is activated to release the environmental agent. This targeted and controlled release enables more efficient and effective environmental remediation. The new claims provide specific embodiments of this concept, including systems for agricultural pest control, methods for reducing environmental pollution, compositions for bioremediation, and systems for wastewater treatment.

Novelty and Inventive Step

The new inventive concept is novel and non-obvious compared to the original patent because it applies the bio-orthogonal chemical reaction technology to entirely new fields of environmental applications, providing a unique solution to the problems of pest control, pollution, and wastewater treatment.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different bio-orthogonal chemical reaction triggers and activators, or the adaptation of the technology to other environmental applications, such as soil remediation or air pollution control.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the environmental industry, with potential applications in agriculture, bioremediation, wastewater treatment, and pollution control. The target market includes companies and organizations involved in environmental remediation, as well as government agencies responsible for environmental regulation and protection.

CPC Classifications

SectionClassGroup
A A61 A61K47/6803
A A61 A61K31/435
A A61 A61K31/444
A A61 A61K31/704
A A61 A61K38/05
A A61 A61K39/3955
A A61 A61K39/39558
A A61 A61K47/22
A A61 A61K47/545
A A61 A61K47/555
A A61 A61K47/558
A A61 A61K47/6897
B B82 B82Y5/00
C C07 C07C33/16
C C07 C07D237/26
C C07 C07D257/08
Y Y02 Y02A50/30

Field of Art

Chemical biology, pharmaceutical chemistry, and bio-orthogonal reaction technologies with expertise in prodrug design, targeted drug delivery, and chemical activation mechanisms

Person of Ordinary Skill (PHOSITA) Profile

A PhD-level chemist or chemical engineer with advanced training in organic synthesis, bioconjugation techniques, and experience designing controlled-release chemical systems with interdisciplinary knowledge spanning medicinal chemistry, environmental science, and chemical engineering

Obviousness Rationale

The PTD represents a straightforward extension of the source patent's bio-orthogonal chemical reaction technology by applying the core prodrug activation mechanism to environmental applications. A PHOSITA would recognize that the fundamental trans-cyclooctene/tetrazine cyclooaddition reaction mechanism can be readily adapted across different domains by simply substituting the payload molecule. The technical principles of controlled, targeted chemical activation remain consistent between medical and environmental contexts.

Obvious Combinations & Variations

Source Patent Element
Bio-orthogonal chemical reaction for activating inactivated compounds
PTD Variation
Applying the same reaction mechanism to activate environmental agents like pesticides and bioremediation compounds
Obviousness Reasoning
Known technique of transferring a proven chemical activation method across technical domains with predictable results
Source Patent Element
Prodrug design using trans-cyclooctene derivatives
PTD Variation
Conjugating environmental agents to trans-cyclooctene instead of pharmaceutical molecules
Obviousness Reasoning
Routine design choice involving simple molecular substitution with expected chemical behavior
Source Patent Element
Tetrazine-mediated chemical activation
PTD Variation
Using tetrazine derivatives to trigger release of environmental treatment agents
Obviousness Reasoning
Predictable extension of known bio-orthogonal reaction principles to alternative molecular payloads
Source Patent Element
Controlled chemical release mechanism
PTD Variation
Implementing targeted release for pest control, pollution remediation, and wastewater treatment
Obviousness Reasoning
Obvious application of established chemical activation strategy to solve related technical problems
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857636, a person having ordinary skill in the art would find the environmental applications disclosed herein to be obvious variations of the fundamental bio-orthogonal chemical activation method. The systematic adaptation of prodrug activation principles to environmental agent delivery represents a predictable technological extension employing known chemical techniques, thereby rendering potential claims in this domain obvious and unpatentable.

Original Patent Information

Patent NumberUS 11,857,636
TitleBio-orthogonal drug activation
Assignee(s)Tagworks Pharmaceuticals B.V.